Sign up USA
Proactive Investors - Run By Investors For Investors

Eli Lilly tops 3Q earnings and revenue forecasts while lifting guidance; shares climb

Stronger revenue was driven by new medicines and prudent expense management
pills
Eli Lilly is a global pharmaceutical company which is based in Indianapolis, Indiana

Drug maker Eli Lilly (NYSE:LLY) topped third-quarter earnings and revenue estimates while lifting EPS guidance due to strong sales as shares edged higher in premarket trade on Tuesday.

The company said EPS came in at $1.39, up against the consensus of $1.35 and the year-ago level of $1.05. Revenue reached $6.06 billion which is 7% higher than the year-ago mark of $5.66 billion and just above the consensus of $6.05 billion.

"Lilly delivered strong financial results in the third quarter. Revenue growth (was) driven by greater use of our newest medicines, coupled with prudent expense management, led to strong EPS growth," said David Ricks, Lilly's chairman and CEO.

Shares of Eli Lilly rose 0.7% to $110.94 in the premarket, having settled 3.18% higher on Monday at $110.14.

READ: Eli Lilly raises full-year earnings guidance; flags plans to float Elanco Animal Health

"Our strategy is to focus on discovering and developing breakthrough medicines that can help doctors and patients who need new treatment options for serious diseases. We are pleased with our progress this quarter, achieving key development and regulatory milestones in pain and diabetes, while driving continued adoption of our new medicines around the world. Consistent with our revised guidance, we expect to finish 2018 by further delivering strong performance," added Ricks.

The increase in revenue was driven by a 12% increase due to volume, partially offset by a 4% decrease due to lower realized prices and a 1% decrease due to the unfavorable impact of foreign exchange rates, the company said.

The new drug Trulicity, which overtook diabetes drug Humalog as Lilly's best-selling medicine, rang up revenue of $816.2 million in the three months ending in September, higher by around 55% from a year earlier. 

Revenue in the US increased 11% to $3.447 billion, driven primarily by increased volume for new pharmaceutical products, including Trulicity, Basaglar, Taltz, and Verzenio. The increase in revenue was partially offset by lower realized prices, primarily driven by Basaglar, Humalog and Taltz, as well as decreased volume for products that have lost exclusivity, including Cialis, Strattera and Effient.

READ: Eli Lilly 1Q earnings beat Street, but FDA delivers disappointing recommendation for new arthritis drug

Revenue outside the US increased 2% to $2.615 billion, driven by increased volume of 8%, which was primarily for new pharmaceutical products, including Trulicity, Olumiant and Taltz. The increase in revenue was partially offset by lower realized prices for several pharmaceutical products, decreased volume for erectile dysfunction drug Cialis due to loss of exclusivity, as well as the unfavorable impact of foreign exchange rates.

The company said new medicines such as Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Verzenio, Lartruvo and Olumiant accounted for 35% of pharma revenue and drove strong volume growth.

The company said its 2018 EPS guidance range was revised higher to $3.04 to $3.09 on a reported basis and $5.55 to $5.60 on a non-GAAP basis.

Eli Lilly is a global pharmaceutical company which is based in Indianapolis, Indiana.

Reporting by Rene Pastor, contactable on [email protected]

View full LLY profile View Profile

Eli Lilly Timeline

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use